Dexcom Inc launches redesigned Stelo app, shares trade around key Nasdaq level

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 13:50.

Dexcom Inc (US2521311074) is setting up a July rollout of its redesigned Stelo glucose app as it prepares launches in four new countries, according to Simply Wall St and Nasdaq data for DXCM on NASDAQ. The healthcare equipment stock trades on NASDAQ around 70 dollars per share after a year-to-date gain of about 5 percent but a double-digit decline over the past year.

Stelo app and new markets

Sydney-based Simply Wall St reports that Dexcom plans to roll out a redesigned Stelo app in July to provide more accessible and actionable glucose insights to users, following recent FDA clearance for over-the-counter pediatric use of the Stelo Glucose Biosensor System in the United States. The same analysis notes that Dexcom is preparing to launch Stelo in the United Kingdom, Australia, New Zealand, and South Korea, marking a push into new international markets alongside its established U.S. base.

According to the Simply Wall St note, Dexcom shares trade around 70.14 dollars, with the stock up 5.4 percent year to date but down 18.8 percent over the past 12 months and off 45.4 percent over three years. The service highlights that these product and geographic moves come as investors reassess the long-term growth trajectory of continuous glucose monitoring relative to other U.S. healthcare equipment peers such as Abbott Laboratories and Medtronic.

Analyst coverage and valuation context

Robinhood's data for Dexcom shows a market capitalization of about 27.06 billion dollars and a price-to-earnings ratio near 29 based on recent trading around 70.14 dollars. The same source notes a one-day trading range between 68.02 and 70.38 dollars for DXCM, placing the closing price roughly 3.1 percent above the day’s low and 0.3 percent below the high.

Robinhood cites a recent analyst update where Deutsche Bank initiated coverage of Dexcom with a Buy rating and an 86 dollar price target, stating the company "could be turning a corner" after a recent investor day eased some concerns around growth and margins. The analyst comment adds to a broader consensus picture in which several U.S. research houses continue to view Dexcom as a key player in continuous glucose monitoring for both diabetes management and emerging consumer segments.

The product behind the stock

Dexcom’s core business centers on continuous glucose monitoring systems such as the Dexcom G7, which provide real-time glucose readings via a small wearable sensor and a paired mobile app. The newly redesigned Stelo app sits alongside these systems, aiming to broaden access to glucose biosensing beyond intensive diabetes management into preventive and lifestyle-oriented use cases.

Where the shares trade today

Dexcom Inc shares (US2521311074) last closed on NASDAQ on 2026-06-26 at 70.14 US dollars, based on Robinhood quote data. Extended trading after the closing bell showed DXCM changing hands near 69.72 dollars, reflecting modest after-hours volatility in the U.S. healthcare equipment segment.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. All data are based on sources cited in the text and may be subject to change.